Nora Therapeutics Names Sandra Shpilberg Vice President, Strategic Marketing & Commercial Planning

PALO ALTO, Calif., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced that Sandra Shpilberg has been named Vice President, Strategic Marketing & Commercial Planning. Ms. Shpilberg will be responsible for the development and implementation of marketing and commercial strategies for Nora's lead compound, NT100.

"We are delighted to welcome Sandra to the Nora team," said Jeffrey K. Tong, Ph.D., President and CEO of Nora Therapeutics. "Her marketing and product launch experience, combined with her background in working with patients and physicians in areas of high unmet need, including orphan indications, will be invaluable to Nora as we continue advancing NT100 toward the marketplace as a potential new treatment option for women who have experienced multiple IVF failures or who have suffered from recurrent miscarriages."

"I'm thrilled to be joining Nora at such a pivotal time for the company," said Ms. Shpilberg. "I'm passionate about bringing novel therapies to market for conditions with true unmet needs, and look forward to contributing to the development of the company and of NT100."

Ms. Shpilberg brings biopharmaceutical marketing, development, and product launch experience to Nora, most recently serving as Executive Director, Product Development at BioMarin Pharmaceutical Inc. During her tenure at BioMarin, she led the company's commercial launch of KUVAN®, a first-to-market medicine for Phenylketonuria, advanced BMN-165, an investigational injectable for Phenylketonuria, from Phase 2 to Phase 3, directed the lifecycle planning for in-market products ALDURAZYME®, NAGALAZYME® and VIMIZIM®, and oversaw the management of strategic alliances with Genzyme and Merck Serono. The work on the launch of KUVAN® earned her and the company several industry awards, including a Medical Marketing & Media Award and a Webby Award Honor. Prior to BioMarin, Ms. Shpilberg was involved in the marketing of REMICADE® at Centocor, a Johnson & Johnson biotechnology company.

Ms. Shpilberg has an MBA in Marketing and Entrepreneurial Management from The Wharton School at the University of Pennsylvania.

About Nora Therapeutics, Inc.

Nora Therapeutics is a privately held biotechnology company focused on developing therapeutics to address IVF failure and recurrent pregnancy loss, two reproductive conditions with significant unmet need. Nora's lead compound, NT100, is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract and may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. For more information, please visit

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.